Sherman Oaks, CA, United States of America

Michael D Bartberger

This inventor holds 26 USPTO granted patents and 15 published patent applications, plus 5 CIPO patents and 12 EPO patents, primarily in Cancer Therapeutics. Top assignees: Amgen Inc., Alterome Therapeutics, Inc., Biovitrum Ab. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael D Bartberger. Retrieved from https://idiyas.com/inventor/michael-d-bartberger

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 26 (Patent Applications = 15)

% Patents Active = 76.9

CIPO Patents = 5 (Patent Applications = 11)

EPO Patents = 12 (Patent Applications = 18)

Average Co-Inventor Count = 10.9

ph-index = 8

Forward Citations = 154(Granted Patents)

Location History:

Thousand Oaks, CA (US) (2021)
Sherman Oaks, CA (US) (2007 - 2024)

Company Filing History:

Alterome Therapeutics, Inc.

California Institute of Technology

patents

6. 3 out of 16,035

University of California

patents

7. 1 out of 127

Teijin Pharma Limited

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

KRAS Inhibitors

CDK Inhibitors

MDM2 Inhibitors

Beta-Secretase Modulators

Heterocyclic Compounds

Pyrido Compounds

Glucokinase Regulatory Protein

11-Beta-Hydroxysteroid Dehydrogenase

Cancer Treatment

Diabetes Treatment

Inhibitors

Pharmaceutical Compounds

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583859 - PRMT5 inhibitors and uses thereof (2026-03-24),

2. 12528828 - Substituted pyrido[4,3-d]pyrimidines as KRAS modulators (2026-01-20),

3. 12486280 - CDK inhibitors and uses thereof (2025-12-02),

4. 12466842 - Substituted pyrido [4,3-d]pyrimidines as KRAS modulators (2025-11-11),

5. 12428416 - ERK inhibitors and uses thereof (2025-09-30),

6. 12209087 - AKT1 modulators (2025-01-28),

7. 11999730 - AKT1 modulators (2024-06-04),

8. 11407721 - CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer (2022-08-09),

9. 11332459 - Benzimidazole derivatives and their uses (2022-05-17),

10. 11096939 - KRAS G12C inhibitors and methods of using the same (2021-08-24),

11. 11045484 - KRAS G12C inhibitors and methods of using the same (2021-06-29),

12. 10988485 - KRAS G12C inhibitors and methods of using the same (2021-04-27),

13. 9593129 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2017-03-14),

14. 9376425 - Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer (2016-06-28),

15. 9296736 - Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer (2016-03-29),

Title: The Innovative Journey of Michael D Bartberger

Introduction: Michael D Bartberger, a talented inventor hailing from Sherman Oaks, CA, has made significant contributions to the world of technology and innovation.

Latest Patents: Michael D Bartberger holds several patents in the field of electronics and software development, with his latest patent focusing on a groundbreaking artificial intelligence algorithm for autonomous vehicles.

Career Highlights: With a career spanning over two decades, Michael D Bartberger has worked for leading tech companies, where he spearheaded research and development projects that have resulted in cutting-edge inventions.

Collaborations: Throughout his career, Michael D Bartberger has collaborated with top engineers, designers, and scientists to bring his innovative ideas to life. His collaborative spirit has led to the successful implementation of various patented technologies.

Conclusion: Michael D Bartberger's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors. His contributions have undoubtedly left a lasting impact on the world of inventions and patents.

Profile summary based on public USPTO records.